NMD Pharma A/S - CVR: 36899069

2023, EUR

24.06.2024

Bruttoresultat

-19.182'

Primær drift

-23.241'

Årets resultat

-22.401'

Aktiver

46.393'

Kortfristede aktiver

46.111'

Egenkapital

42.673'

Afkastningsgrad

-50 %

Soliditetsgrad

92 %

Likviditetsgrad

+500%

Resultat

24.06.2024

Årsrapport	2023 24.06.2024	2022 04.07.2023	2021 15.06.2022	2020 17.06.2021	2019 27.04.2020	2018 28.05.2019	2017 01.06.2018	2016 24.05.2017	2015 25.05.2016
Nettoomsætning
Bruttoresultat	-19.182.079	-9.480.436	-11.029.051	-7.870.124	-7.132.039	-4.661.848	-17.857.762	0	0
Resultat af primær drift	-23.240.655	-12.980.225	-14.252.927	-10.613.126	-9.145.166	-6.169.955	-25.620.167	-8.527.892	-26.073
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0	0	0	0	0
Finansielle indtægter	107.499	0	0	0	0	0	51.230	0	0
Finansieringsomkostninger	-4.840	-80.324	-97.715	-51.461	-92.667	-109.434	-1.234.852	-46.827	-1.270
Andre finansielle omkostninger	0	0	0	0	0	0	0	0	0
Resultat før skat	-23.137.996	-13.060.549	-14.350.642	-10.664.587	-9.237.833	-6.279.389	-26.803.789	-8.574.719	-27.343
Resultat	-22.401.436	-12.323.989	-13.614.082	-9.928.027	-8.501.273	-5.542.829	-21.883.435	-6.872.801	-27.343
Forslag til udbytte	0	0	0	0	0	0	0	0	0

Aktiver

24.06.2024

Årsrapport	2023 24.06.2024	2022 04.07.2023	2021 15.06.2022	2020 17.06.2021	2019 27.04.2020	2018 28.05.2019	2017 01.06.2018	2016 24.05.2017	2015 25.05.2016
Kortfristede varebeholdninger	0	0	0	0	0	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	1.050.307	1.140.480	1.023.009	1.962.593	887.557	894.485	5.581.651	2.096.395	31.002
Likvider	45.060.423	25.820.863	3.815.827	9.448.988	9.177.320	5.847.901	15.757.308	12.355.775	656
Kortfristede aktiver	46.110.730	26.961.343	4.838.836	11.411.581	10.064.877	6.742.386	21.338.959	14.452.170	31.658
Immaterielle aktiver og goodwill	0	0	0	0	0	0	0	0	0
Finansielle anlægsaktiver	121.292	82.611	80.910	76.968	0	0	0	0	0
Materielle aktiver	160.603	94.610	0	0	0	0	0	0	0
Langfristede aktiver	281.895	177.221	80.910	76.968	0	0	0	0	0
Aktiver	46.392.625	27.138.564	4.919.746	11.488.549	10.064.877	6.742.386	21.338.959	14.452.170	31.658

Aktiver

24.06.2024

Passiver

24.06.2024

Årsrapport	2023 24.06.2024	2022 04.07.2023	2021 15.06.2022	2020 17.06.2021	2019 27.04.2020	2018 28.05.2019	2017 01.06.2018	2016 24.05.2017	2015 25.05.2016
Forslag til udbytte	0	0	0	0	0	0	0	0	0
Egenkapital	42.672.873	25.132.967	2.595.580	9.243.117	6.696	6.696	-8.733.578	13.149.857	22.658
Hensatte forpligtelser	0	0	0	0	0	0	0	0	0
Langfristet gæld til banker	0	0	0	0	0	0	0	0	0
Anden langfristet gæld		0	201.313	201.313	63.455	0	0	0	0
Leverandører af varer og tjenesteydelser	3.016.393	1.526.017	1.669.170	1.446.566	1.465.474	773.502	2.570.658	838.626	0
Kortfristede forpligtelser	3.719.752	2.005.597	2.122.853	2.044.119	1.790.290	995.281	30.072.537	1.302.313	9.000
Gældsforpligtelser	3.719.752	2.005.597	2.324.166	2.245.432	1.853.745	995.281	30.072.537	1.302.313	9.000
Forpligtelser	3.719.752	2.005.597	2.324.166	2.245.432	1.853.745	995.281	30.072.537	1.302.313	9.000
Passiver	46.392.625	27.138.564	4.919.746	11.488.549	10.064.877	6.742.386	21.338.959	14.452.170	31.658

Passiver

24.06.2024

Nøgletal

24.06.2024

Årsrapport	2023 24.06.2024	2022 04.07.2023	2021 15.06.2022	2020 17.06.2021	2019 27.04.2020	2018 28.05.2019	2017 01.06.2018	2016 24.05.2017	2015 25.05.2016
Afkastningsgrad	-50,1 %	-47,8 %	-289,7 %	-92,4 %	-90,9 %	-91,5 %	-120,1 %	-59,0 %	-82,4 %
Dækningsgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Resultatgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	-52,5 %	-49,0 %	-524,5 %	-107,4 %	-126.960,5 %	-82.778,2 %	250,6 %	-52,3 %	-120,7 %
Payout-ratio	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	-480.178,8 %	-16.159,8 %	-14.586,2 %	-20.623,6 %	-9.868,8 %	-5.638,1 %	-2.074,8 %	-18.211,5 %	-2.053,0 %
Soliditestgrad	92,0 %	92,6 %	52,8 %	80,5 %	0,1 %	0,1 %	-40,9 %	91,0 %	71,6 %
Likviditetsgrad	1.239,6 %	1.344,3 %	227,9 %	558,3 %	562,2 %	677,4 %	71,0 %	1.109,7 %	351,8 %

Resultat

24.06.2024

Gæld

24.06.2024

Årsrapport

24.06.2024

Nyeste:01.01.2023- 31.12.2023(offentliggjort: 24.06.2024)

Information om virksomhedens regnskabsklasse:The annual report of NMD Pharma A/S for 2023 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities.

Beretning

24.06.2024

Dato for ledelsens godkendelse af årsrapporten:2024-06-21

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Executive Board have discussed and approved the annual report of NMD Pharma A/S for the financial year 1 January - 31 December 2023.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:NMD Pharma discovers and develops novel therapeutics for neuromuscular diseases and develops small molecule inhibitors of skeletal muscle-specific ClC-1 ion channels with a promising therapeutic potential in a range of neuromuscular diseases. Major activities and achievements in NMD Pharma are listed in the following: In May 2023, NMD Pharma initiated a Phase I trial of NMD1343 in healthy volunteers. In September 2023, NMD Pharma initiated a Phase II trial of NMD670 in Spinal Muscular Atrophy Type 3. In November 2023, NMD Pharma raised new financing of EUR 75 million of which EUR 40 million have been received in 2023 to further expand its clinical programs into several neuromuscular diseases and expand its pipeline against novel targets. The financing was led by Jeito Capital and included investments from existing NMD Pharma investors; INKEF Capital, Novo Holdings, Roche Venture Fund and Lundbeck BioCapital.